IMPACT THERAP-B: Multiple Research Abstract Summaries Accepted for Poster Presentation at 2026 European Society for Medical Oncology Congress

Stock News07-20

The latest clinical data from three key pipeline projects (namely senaparib (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004)) have been accepted for poster presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.

The accepted data includes: (i) the latest progression-free survival (PFS) data from the Phase III FLAMES study of senaparib as first-line maintenance therapy for advanced ovarian cancer; (ii) the latest data from multiple cohorts of the ongoing Phase I/II study of IMP1734, covering monotherapy, combination therapy with paclitaxel for advanced solid tumors, and combination therapy with abiraterone for metastatic prostate cancer; and (iii) preliminary results from the first-in-human Phase I/II study of IMP1707, a central nervous system-penetrant selective PARP1 inhibitor, in patients with HRR-mutated advanced solid tumors.

The ESMO Congress is one of the most influential academic conferences in the global oncology field. This year's congress is scheduled to take place in Madrid, Spain, from October 23 to 27, 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116790823?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 07:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116790823","market":"fut","top_or_hot":-1,"title":"IMPACT THERAP-B: Multiple Research Abstract Summaries Accepted for Poster Presentation at 2026 European Society for Medical Oncology Congress","media":"Stock News","content":"<p>The latest clinical data from three key pipeline projects (namely senaparib (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004)) have been accepted for poster presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.<br><br>The accepted data includes: (i) the latest progression-free survival (PFS) data from the Phase III FLAMES study of senaparib as first-line maintenance therapy for advanced ovarian cancer; (ii) the latest data from multiple cohorts of the ongoing Phase I/II study of IMP1734, covering monotherapy, combination therapy with paclitaxel for advanced solid tumors, and combination therapy with abiraterone for metastatic prostate cancer; and (iii) preliminary results from the first-in-human Phase I/II study of IMP1707, a central nervous system-penetrant selective PARP1 inhibitor, in patients with HRR-mutated advanced solid tumors.<br><br>The ESMO Congress is one of the most influential academic conferences in the global oncology field. This year's congress is scheduled to take place in Madrid, Spain, from October 23 to 27, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMPACT THERAP-B: Multiple Research Abstract Summaries Accepted for Poster Presentation at 2026 European Society for Medical Oncology Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMPACT THERAP-B: Multiple Research Abstract Summaries Accepted for Poster Presentation at 2026 European Society for Medical Oncology Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-20 07:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The latest clinical data from three key pipeline projects (namely senaparib (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004)) have been accepted for poster presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.<br><br>The accepted data includes: (i) the latest progression-free survival (PFS) data from the Phase III FLAMES study of senaparib as first-line maintenance therapy for advanced ovarian cancer; (ii) the latest data from multiple cohorts of the ongoing Phase I/II study of IMP1734, covering monotherapy, combination therapy with paclitaxel for advanced solid tumors, and combination therapy with abiraterone for metastatic prostate cancer; and (iii) preliminary results from the first-in-human Phase I/II study of IMP1707, a central nervous system-penetrant selective PARP1 inhibitor, in patients with HRR-mutated advanced solid tumors.<br><br>The ESMO Congress is one of the most influential academic conferences in the global oncology field. This year's congress is scheduled to take place in Madrid, Spain, from October 23 to 27, 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1116790823","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116790823","pubTimestamp":1784504433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The latest clinical data from three key pipeline projects (namely senaparib (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004)) have been accepted for poster presentation...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","07630":"英派药业-B"},"translate_title":"IMPACT THERAP-B：多项研究摘要被接受用于 2026 年欧洲肿瘤内科学会大会海报展示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"The latest clinical data from three key pipeline projects (namely senaparib (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004)) have been accepted for poster presentation at the 2026 European Society for Medical Oncology (ESMO) Congress.The accepted data includes: (i) the latest progression-free survival (PFS) data from the Phase III FLAMES study of senaparib as first-line maintenance therapy for advanced ovarian cancer; (ii) the latest data from multiple cohorts of the ongoing Phase I/II study of IMP1734, covering monotherapy, combination therapy with paclitaxel for advanced solid tumors, and combination therapy with abiraterone for metastatic prostate cancer; and (iii) preliminary results from the first-in-human Phase I/II study of IMP1707, a central nervous system-penetrant selective PARP1 inhibitor, in patients with HRR-mutated advanced solid tumors.The ESMO Congress is one of the most influential academic conferences in the global oncology field. This year's congress is scheduled to take place in Madrid, Spain, from October 23 to 27, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116790823","isCrawlerRequest":true}